Hospital CEO Bonuses Reward Volume And Growth
Profiting From Pain
By BARRY MEIER
THE use of narcotic painkillers, or opioids, has boomed over the past decade as drug makers and doctors have promoted them for a new use: treating long-term pain from back injuries, headaches, arthritis and conditions like fibromyalgia. Insurers have also grown to see pills as a cheaper way to treat chronic pain than other methods.
Some patients are greatly helped by opioids, a large family of medications. Among the more widely used opioids are oxycodone, which is found in Percocet and OxyContin, and hydrocodone, which is used in Vicodin. Other potent opioids include fentanyl and methadone. Narcotic painkillers are now the most widely prescribed class of medications in the United States, and prescriptions for the strongest opioids, including OxyContin, have increased nearly fourfold over the past decade.
There is increasing evidence, however, that such drugs, along with being widely abused, are often ineffective in treating long-term pain and can have serious consequences, particularly when used in high doses. Along with the risk of addiction, side effects can include psychological dependence, reduced drive, extreme lethargy and sleep apnea.
The economic costs associated with the painkiller boom have also proved enormous, giving rise to a host of unanticipated medical, legal and social costs. Over the past decade, the legal — and illegal — use of these drugs has given birth to new businesses and expanded existing ones. These include urine-screening tests to make sure patients are taking the drugs properly, added sales of addiction treatment drugs, growing emergency-room expenses, law-enforcement budgets and skyrocketing costs for insurers.
In the short run, treating a patient with an opioid like OxyContin, which costs about $6,000 a year, is less expensive than putting a patient through a pain-treatment program that emphasizes physical therapy and behavior modification. But over time, such programs, which run from $15,000 to $25,000, might yield far lower costs.
Here is a brief guide to the economics of opioids.
Cure for affordable medical devices
| |
For years, Medicare has been paying sky-high prices for basic equipment like wheelchairs and walkers based on outdated and overpriced payment rates. It was a great deal for the industry, but not a great one for taxpayers and people with Medicare. These inflated Medicare payment rates also helped fuel the rampant proliferation fraud, waste and abuse of durable medical equipment, prosthetics, orthotics and supplies — or DMEPOS — benefit. In 2011, as required by law, CMS implemented a DMEPOS competitive bidding program to bring prices for certain medical equipment and supplies in line with the current market, and to help limit fraud and abuse in the Medicare program. The program has saved more than $400 million in its first two years of operation in only nine areas of the country without diminishing beneficiary access to quality equipment or resulting in negative health outcomes for beneficiaries. This program is a great example of a successful bipartisan initiative passed by a Republican Congress in 2003 and ultimately implemented by the Obama administration to put the brakes on runaway DMEPOS spending. In The Washington Post on June 16, the editorial board pointed out, “Between 2000 and 2010, Medicare spent $69.4 billion on outdated — and inflated — DMEPOS reimbursement rates” and it urged CMS not to delay this important program. Now this successful program is expanding to 91 additional areas on July 1, allowing more beneficiaries across the country to benefit from fair prices on quality medical equipment and supplies. In addition, we are implementing a national mail-order program for diabetic testing supplies. For the second round of the program, CMS is projecting savings of 45 percent below the current fee schedule for DMEPOS items, and savings for the national mail-order program are estimated at 72 percent below the current fee schedule. The program is estimated to save nearly $43 billion over the next 10 years. Medicare and taxpayers will save as much as $25.8 billion, and people with Medicare are projected to save $17.2 billion in reduced co-insurance and premiums. |
No comments:
Post a Comment